Merck KGaA (OTCMKTS:MKGAF) Raised to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Merck KGaA (OTCMKTS:MKGAF) to a strong-buy rating in a report released on Thursday, Zacks.com reports.

Merck KGaA Stock Down 3.4 %

Shares of OTCMKTS MKGAF opened at $182.55 on Thursday. The firm has a market cap of $23.59 billion, a price-to-earnings ratio of 26.81 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. Merck KGaA has a 52-week low of $143.46 and a 52-week high of $200.56. The business’s 50 day moving average is $183.00 and its two-hundred day moving average is $175.49.

Merck KGaA (OTCMKTS:MKGAF) last announced its earnings results on Thursday, August 1st. The company reported $1.51 earnings per share (EPS) for the quarter. The company had revenue of $5.76 billion for the quarter. Merck KGaA had a return on equity of 10.17% and a net margin of 12.60%. Research analysts predict that Merck KGaA will post 9.5 EPS for the current year.

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.